GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GreenLight Biosciences Holdings PBC (NAS:GRNA) » Definitions » Piotroski F-Score

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Piotroski F-Score : N/A (As of Apr. 26, 2024)


View and export this data going back to 2022. Start your Free Trial

What is GreenLight Biosciences Holdings PBC Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GreenLight Biosciences Holdings PBC has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for GreenLight Biosciences Holdings PBC's Piotroski F-Score or its related term are showing as below:

During the past 4 years, the highest Piotroski F-Score of GreenLight Biosciences Holdings PBC was 4. The lowest was 4. And the median was 4.


GreenLight Biosciences Holdings PBC Piotroski F-Score Historical Data

The historical data trend for GreenLight Biosciences Holdings PBC's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GreenLight Biosciences Holdings PBC Piotroski F-Score Chart

GreenLight Biosciences Holdings PBC Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
N/A N/A N/A 4.00

GreenLight Biosciences Holdings PBC Quarterly Data
Dec19 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A 4.00 N/A

Competitive Comparison of GreenLight Biosciences Holdings PBC's Piotroski F-Score

For the Biotechnology subindustry, GreenLight Biosciences Holdings PBC's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GreenLight Biosciences Holdings PBC's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GreenLight Biosciences Holdings PBC's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where GreenLight Biosciences Holdings PBC's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Net Income was -51.926 + -38.158 + -38.764 + -28.469 = $-157.32 Mil.
Cash Flow from Operations was -22.654 + -39.977 + -24.589 + -31.06 = $-118.28 Mil.
Revenue was 1.748 + 1.689 + 2.947 + 3.82 = $10.20 Mil.
Gross Profit was 1.748 + 1.689 + 2.947 + 3.82 = $10.20 Mil.
Average Total Assets from the begining of this year (Mar22)
to the end of this year (Mar23) was
(122.43 + 98.81 + 151.418 + 148.598 + 113.689) / 5 = $126.989 Mil.
Total Assets at the begining of this year (Mar22) was $122.43 Mil.
Long-Term Debt & Capital Lease Obligation was $59.56 Mil.
Total Current Assets was $37.70 Mil.
Total Current Liabilities was $31.19 Mil.
Net Income was -27.174 + -29.181 + -34.672 + -38.207 = $-129.23 Mil.

Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Average Total Assets from the begining of last year (Mar21)
to the end of last year (Mar22) was
(0 + 0 + 63.292 + 63.058 + 122.43) / 5 = $82.92666667 Mil.
Total Assets at the begining of last year (Mar21) was $0.00 Mil.
Long-Term Debt & Capital Lease Obligation was $23.69 Mil.
Total Current Assets was $96.95 Mil.
Total Current Liabilities was $29.52 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GreenLight Biosciences Holdings PBC's current Net Income (TTM) was -157.32. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

GreenLight Biosciences Holdings PBC's current Cash Flow from Operations (TTM) was -118.28. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar22)
=-157.317/122.43
=-1.28495467

ROA (Last Year)=Net Income/Total Assets (Mar21)
=-129.234/0
=

GreenLight Biosciences Holdings PBC's return on assets of this year was -1.28495467. GreenLight Biosciences Holdings PBC's return on assets of last year was . ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

GreenLight Biosciences Holdings PBC's current Net Income (TTM) was -157.32. GreenLight Biosciences Holdings PBC's current Cash Flow from Operations (TTM) was -118.28. ==> -118.28 > -157.32 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=59.56/126.989
=0.469017

Gearing (Last Year: Mar22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar21 to Mar22
=23.686/82.92666667
=0.28562585

GreenLight Biosciences Holdings PBC's gearing of this year was 0.469017. GreenLight Biosciences Holdings PBC's gearing of last year was 0.28562585. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar23)=Total Current Assets/Total Current Liabilities
=37.697/31.187
=1.20874082

Current Ratio (Last Year: Mar22)=Total Current Assets/Total Current Liabilities
=96.948/29.524
=3.2837014

GreenLight Biosciences Holdings PBC's current ratio of this year was 1.20874082. GreenLight Biosciences Holdings PBC's current ratio of last year was 3.2837014. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

GreenLight Biosciences Holdings PBC's number of shares in issue this year was 151.614. GreenLight Biosciences Holdings PBC's number of shares in issue last year was 113.558. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=10.204/10.204
=1

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

GreenLight Biosciences Holdings PBC's gross margin of this year was 1. GreenLight Biosciences Holdings PBC's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar22)
=10.204/122.43
=0.08334559

GreenLight Biosciences Holdings PBC's asset turnover of this year was 0.08334559. GreenLight Biosciences Holdings PBC's asset turnover of last year was . ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

GreenLight Biosciences Holdings PBC has an F-score of 4 indicating the company's financial situation is typical for a stable company.

GreenLight Biosciences Holdings PBC  (NAS:GRNA) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


GreenLight Biosciences Holdings PBC Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of GreenLight Biosciences Holdings PBC's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Business Description

Traded in Other Exchanges
N/A
Address
29 Hartwell Avenue, Lexington, MA, USA, 02421
GreenLight Biosciences Holdings PBC is a pre-commercial stage synthetic biology company with a proprietary cell-free ribonucleic acid production platform for the discovery, development, and commercialization of high-performing products to promote healthier plants, foods, and people. The company is developing RNA products for plant and life science applications to advance crop management, plant protection, animal health, vaccine development, and pandemic preparation.
Executives
Deval L Patrick other: See Remarks BAIN CAPITAL, LLC, 200 CLARENDON STREET, BOSTON MA 02116
Dennis A. Clarke other: Member of 13D group owning 10% 6 FERNWAY TERRACE, WINCHESTER MA 01890
Cummings Foundation, Inc. other: Member of 13D group owning 10% 200 WEST CUMMINGS PARK, WOBURN MA 01801
Eric Senior Anderson other: Member of 13D group owning 10% 25 N HILL ROAD, WESTOVER MA 01886
Mls Capital Fund Ii Lp other: See remarks C/O MLSC II (GP) (LABUAN) LLP, ONE MARKET ST SUITE 3525, SAN FRANCISCO CA 94105
Chelt Trading Ltd other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 3RD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Highview Trust other: Member of 13D Group C/O FOX HORAN & CAMERINI LLP, 885 THIRD AVENUE, 17TH FLOOR, NEW YORK NY 10022
Montealegre Lacayo Jaime Javier other: Member of 13D Group APARTADO 15-1250, ESCAZU G2
Furneaux Capital Holdco, Llc other: Member of 13D group 1 MARINA PARK DRIVE, BOSTON MA 02210
Lewis & Clark Plant Sciences Fund I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Lewis & Clark Ventures I, Lp other: Member of 13D group 120 S. CENTRAL AVENUE, SUITE 1000, ST. LOUIS MO 63105
Matthew Allen Walker director, 10 percent owner C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Martha Schlicher director C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Marta Ortega-valle other: Member of 10% owner group C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Builders Vision, Llc 10 percent owner 110 NW 2ND STREET SUITE 300, BENTONVILLE AR 72712

GreenLight Biosciences Holdings PBC (GreenLight Biosciences Holdings PBC) Headlines

From GuruFocus